La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Rockwell Medical a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Rockwell Medical..

Rockwell Medical (NASDAQ:RMTI) Azioni, Catena delle Opzioni

Rockwell Medical

Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.

Rockwell Medical Inc

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and lowers the price target from $7 to $3.

News

Price Target

Analyst Ratings

RMTI

HC Wainwright & Co. Maintains Buy on Rockwell Medical, Lowers Price Target to $3

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 226.4% to $1.73 during Thursday's regular session. The market value of their outstanding shares is at $19.9 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares moved upwards by 205.28% to $1.56. The market value of their outstanding shares is at $9.1 million. </li>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) stock moved upwards by 54.63% to $9.28. The company's market cap stands at $93.2 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock rose 31.36% to $2.22. The company's market cap stands at $1.6 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock moved upwards by 27.84% to $11.98. The company's market cap stands at $98.8 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>ARS Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>) stock moved upwards by 26.43% to $14.73. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) stock fell 38.8% to $0.29 during Thursday's regular session. The company's market cap stands at $17.3 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock decreased by 28.51% to $0.32. The market value of their outstanding shares is at $82.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares declined by 28.35% to $2.04. The company's market cap stands at $480.7 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 20.28% to $2.59. The company's market cap stands at $1.7 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares fell 18.76% to $1.43. The market value of their outstanding shares is at $46.2 million. As per the news, the Q4 earnings report came out today. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 17.1% to $1.94. The market value of their outstanding shares is at $1.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADAP

AKBA

BDRX

CRVO

ELEV

OPTN

PSTV

SPRY

VERO

WINT

12 Health Care Stocks Moving In Thursday's Intraday Session

WIIM

Rockwell Medical shares are trading lower. The company reported Q4 financial results.

<h3>Gainers</h3>
<ul>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) shares moved upwards by 58.3% to $9.5 during Thursday's pre-market session. The market value of their outstanding shares is at $95.5 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock increased by 35.5% to $2.29. The company's market cap stands at $1.7 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock rose 20.99% to $0.62. The company's market cap stands at $3.6 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) shares moved upwards by 15.56% to $1.63. The company's market cap stands at $3.4 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares rose 13.01% to $0.85. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) stock rose 12.96% to $11.33. The market value of their outstanding shares is at $11.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) stock decreased by 23.9% to $2.16 during Thursday's pre-market session. The market value of their outstanding shares is at $510.2 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares declined by 16.67% to $1.95. The market value of their outstanding shares is at $1.3 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) shares fell 12.32% to $0.29. The company's market cap stands at $7.3 million. </li>
<li>GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares decreased by 12.32% to $10.4. The market value of their outstanding shares is at $645.0 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares declined by 9.1% to $1.6. The company's market cap stands at $51.7 million. The company's, Q4 earnings came out today. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock decreased by 9.07% to $0.35. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

AEON

GHRS

MHUA

MSPR

TNFA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.02 by 100 percent. This is a 100 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $24.70 million which beat the analyst consensus estimate of $23.65 million by 4.43 percent. This is a 11.80 percent increase over sales of $22.09 million the same period last year.

Earnings

Earnings Beats

Rockwell Medical Q4 2024 Adj EPS $0.04 Beats $0.02 Estimate, Sales $24.70M Beat $23.65M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Star Equity Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRR#NASDAQ">STRR</a>) is projected to report quarterly loss at $0.17 per share on revenue of $14.00 million. 
• Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) is expected to report quarterly earnings at $1.82 per share on revenue of $1.68 billion. 
• Jabil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) is estimated to report quarterly earnings at $1.83 per share on revenue of $6.40 billion. 
• Mogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#NASDAQ">MOGO</a>) is likely to report quarterly loss at $0.08 per share on revenue of $12.77 million. 
• Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) is expected to report earnings for its fourth quarter. 
• Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $7.48 million. 
• InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) is estimated to report quarterly loss at $0.28 per share on revenue of $125 thousand. 
• Beasley Broadcast Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBGI#NASDAQ">BBGI</a>) is likely to report earnings for its fourth quarter. 
• Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $8.42 million. 
• Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) is projected to report quarterly loss at $0.37 per share on revenue of $12.79 million. 
• Bragg Gaming Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRAG#NASDAQ">BRAG</a>) is estimated to report earnings for its fourth quarter. 
• Autolus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>) is likely to report quarterly loss at $0.24 per share on revenue of $2.98 million. 
• Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) is estimated to report quarterly earnings at $2.79 per share on revenue of $3.22 billion. 
• FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) is likely to report quarterly earnings at $4.18 per share on revenue of $570.67 million. 
• Gambling.com Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) is likely to report quarterly earnings at $0.24 per share on revenue of $35.14 million. 
• Destination XL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $120.93 million. 
• Titan Machinery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) is estimated to report quarterly loss at $0.63 per share on revenue of $728.55 million. 
• Designer Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>) is estimated to report quarterly loss at $0.49 per share on revenue of $719.32 million. 
• Caleres (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAL#NYSE">CAL</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $646.05 million. 
• NeueHealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEUE#NYSE">NEUE</a>) is likely to report quarterly loss at $3.99 per share on revenue of $261.80 million. 
• Commercial Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) is estimated to report quarterly earnings at $0.30 per share on revenue of $1.75 billion. 
• Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) is expected to report quarterly earnings at $2.81 per share on revenue of $16.61 billion. 
• ARS Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>) is expected to report quarterly loss at $0.12 per share on revenue of $15.90 million. 
• ZEEKR Intelligent Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>) is projected to report earnings for its fourth quarter. 
• Shoe Carnival (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) is estimated to report quarterly earnings at $0.44 per share on revenue of $275.92 million. 
• 111 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YI#NASDAQ">YI</a>) is expected to report earnings for its fourth quarter. 
• Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $22.61 million. 
• VEON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) is expected to report quarterly earnings at $0.77 per share on revenue of $997.00 million. 
• Valneva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) is estimated to report quarterly loss at $0.22 per share on revenue of $56.43 million. 
• H World Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $798.17 million. 
• 22nd Century Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) is estimated to report earnings for its fourth quarter. 
• Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) is projected to report earnings for its fourth quarter. 
• PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) is likely to report quarterly earnings at $2.56 per share on revenue of $15.68 billion. 
• Yiren Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) is likely to report earnings for its fourth quarter. 
• Neuraxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NRXS#AMEX">NRXS</a>) is likely to report earnings for its fourth quarter. 
• SPDR Select Sector Fund - Consumer Discretionary (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) is projected to report earnings for its fourth quarter. 
• Baozun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZUN#NASDAQ">BZUN</a>) is expected to report earnings for its fourth quarter. 
• Lands' End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $458.69 million. 
<h3>Companies Reporting After The Bell</h3>
• Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) is likely to report quarterly earnings at $0.29 per share on revenue of $11.01 billion. 
• FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) is likely to report quarterly earnings at $4.54 per share on revenue of $21.89 billion. 
• Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) is expected to report quarterly earnings at $1.42 per share on revenue of $7.89 billion. 
• United States Antimony (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAMY#AMEX">UAMY</a>) is estimated to report earnings for its fourth quarter. 
• SANUWAVE Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNWV#NASDAQ">SNWV</a>) is projected to report earnings for its fourth quarter. 
• Motorsport Games (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) is projected to report quarterly loss at $0.48 per share on revenue of $3.30 million. 
• Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) is projected to report earnings for its fourth quarter. 
• Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) is expected to report quarterly loss at $0.05 per share on revenue of $200 thousand. 
• Intellicheck (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDN#NASDAQ">IDN</a>) is likely to report quarterly loss at $0.01 per share on revenue of $5.07 million. 
• Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) is likely to report quarterly loss at $0.11 per share on revenue of $15.68 million. 
• Flux Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLUX#NASDAQ">FLUX</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $14.50 million. 
• Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) is likely to report quarterly loss at $0.85 per share on revenue of $1.75 million. 
• Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) is expected to report quarterly loss at $3.77 per share on revenue of $901 thousand. 
• Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $7.14 million. 
• Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) is projected to report quarterly loss at $0.07 per share on revenue of $263.00 million. 
• Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) is expected to report quarterly earnings at $1.73 per share on revenue of $7.44 billion. 
• Scholastic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCHL#NASDAQ">SCHL</a>) is projected to report quarterly loss at $0.78 per share on revenue of $347.68 million. 
• Arcadia Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKDA#NASDAQ">RKDA</a>) is projected to report quarterly loss at $0.50 per share on revenue of $1.15 million. 
• Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) is estimated to report quarterly loss at $0.66 per share on revenue of $30.93 million. 
• TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) is likely to report quarterly loss at $0.22 per share on revenue of $23.26 million. 
• Ouster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>) is likely to report quarterly loss at $0.26 per share on revenue of $30.00 million. 
• Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) is projected to report quarterly loss at $0.15 per share on revenue of $17.43 million. 
• Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) is expected to report quarterly loss at $0.02 per share on revenue of $62.20 million. 
• KinderCare Learning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $645.37 million. 
• Runway Gwth Fin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RWAY#NASDAQ">RWAY</a>) is likely to report quarterly earnings at $0.41 per share on revenue of $36.19 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALAR

AMPX

AUTL

BBGI

BRAG

BZUN

CBUS

CGTX

CURV

DXLG

FLUX

GAMB

GLUE

HTHT

IFRX

LAZR

MGNX

MOGO

MSGM

NEUE

NRXS

OUST

Citigourp Global Markets 2% Protected Notes Linked To The Djia

QUBT

RKDA

RWAY

SCHL

SCVL

SKYE

SNWV

STRR

TELA

TITN

TNON

UAMY

VALN

VEEE

VEON

VXRT

Select Sector SPDR-Consumer Discretionary

XXII

Earnings Scheduled For March 20, 2025

General

Rockwell Medical Includes Single-Use Bicarbonate Cartridge To Hemodialysis Concentrates Product Portfolio

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and maintains $7 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Rockwell Medical, Maintains $7 Price Target

Rockwell Medical shares are trading higher after the company announced expectations for $10 million in FY25 net sales and entered a purchase agreement with a provider of dialysis products and services.

Rockwell Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares are trading higher premarket on Tuesday after it entered into a product purchase agreement with a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42525272/rockwell-medical-enters-into-a-multi-year-product-purchase-agreement-with-the-worlds-leading-provi" rel="noreferrer noopener">provider of dialysis products and services</a>.
As per the three-year agreement, Rockwell Medical will supply its SteriLyte liquid bicarbonate product to the customer, with an option to renew it for two additional one-year terms.
The agreement is expected to generate over $10 million in net sales in the first year, a portion of which was not included in Rockwell Medical&#8217;s previously announced revenue estimates for 2025, with incremental price increases in subsequent years.
Last week, the company announced the promotion of Jesse Neri to the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42456143/rockwell-medical-promotes-jesse-neri-to-chief-financial-officer" rel="noreferrer noopener">post of Chief Financial Officer</a>.
This month, Rockwell Medical disclosed a partnership with HydroCare in which HydroCare will purchase and install Rockwell&#8217;s DAMX45 dry acid concentrate <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42334338/rockwell-medical-partners-with-hydrocare-to-distribute-and-install-its-dry-acid-concentrate-mix-sy" rel="noreferrer noopener">mix system in dialysis water rooms</a>.
This installation is expected to drive new sales for Rockwell&#8217;s dry acid hemodialysis concentrates.
Also, last month, the company inked a distribution deal with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42057509/rockwell-medical-expands-distribution-in-the-philippines" rel="noreferrer noopener">Nephro Group Dialysis Centers</a>.
Price Action: RMTI shares are up 14.4% at $2.29 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42526136" target="_blank" rel="noreferrer noopener">Asia Mostly Lower, Europe Markets Up As Dollar Strengthens Ahead Of Fed Rate Decision &#8211; Global Markets Today While US Slept</a></li>
</ul>
Image via Shutterstock.

Equities

Contracts

Small Cap

Rockwell Medical Scores Multi-Year Dialysis Deal; Stock Jumps

Under the terms of the Agreement, Rockwell Medical will supply the Customer with the Company's liquid bicarbonate hemodialysis concentrates product, SteriLyte.&nbsp;
The Agreement will remain in effect for three years with the option to renew for two additional one-year periods and is expected to generate upwards of $10 million in net sales for the Company in the first year, a portion of which was not included in Rockwell Medical's previously disclosed revenue estimates for 2025, with incremental price increases each subsequent year.

Rockwell Medical Enters Product Purchase Agreement With AProvider Of Dialysis Products And Services; Partnership Expected To Generate Upwards Of $10M In Net Sales For Company In 2025

Management

Rockwell Medical Promotes Jesse Neri To CFO

Rockwell anticipates that with these new mixer installations through HydroCare, the Company will also generate new sales related to its dry acid hemodialysis concentrates. Rockwell Medical's DAMX45 dry acid concentrate mix system is 510(k) approved to be used exclusively with the Company's CitraPure and Dri-Sate dry acid concentrate powders.&nbsp;

Health Care

Rockwell Medical Has Partnered With Hydrocare To Purchase And Install The Company's Dry Acid Concentrate Mix System In Dialysis Water Rooms

Ratings for Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $7.5, a high estimate of $9.00, and a low estimate of $5.00. This current average has decreased by 16.67% from the previous average price target of $9.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1732543258_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Rockwell Medical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Brandon Folkes</td>
<td>Rodman &amp; Renshaw</td>
<td>Announces</td>
<td>Buy</td>
<td>$5.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Rockwell Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rockwell Medical compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Rockwell Medical's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Rockwell Medical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RMTI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Rockwell Medical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Rockwell Medical</h2>
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
<h3>Key Indicators: Rockwell Medical's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Rockwell Medical's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 19.12%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 5.88%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Rockwell Medical's ROE excels beyond industry benchmarks, reaching 6.32%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Rockwell Medical's ROA excels beyond industry benchmarks, reaching 3.02%. This signifies efficient management of assets and strong financial health.
Debt Management: Rockwell Medical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.49.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Rockwell Medical Stock

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and lowers the price target from $9 to $7.

HC Wainwright & Co. Maintains Buy on Rockwell Medical, Lowers Price Target to $7

Under the terms of the agreement, Rockwell Medical will be the exclusive supplier of all dry hemodialysis concentrates products, including its CitraPure Acid and RenalPure Bicarbonate, to Nephro Group.

Rockwell Medical Enters Distribution Agreement With Nephro Group Dialysis Centers

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Rodman &amp; Renshaw analyst Brandon Folkes initiated coverage on Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) with a Buy rating and announced a price target of $8. Adial Pharmaceuticals shares closed at $0.9910 on Wednesday. See how other analysts view this stock.</li>
<li>Truist Securities analyst Keith Hughes initiated coverage on Carlisle Companies Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) with a Hold rating and announced a price target of $460. Carlisle shares closed at $454.83 on Wednesday. <a href="https://www.benzinga.com/quote/CSL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rodman &amp; Renshaw analyst Brandon Folkes initiated coverage on Achieve Life Sciences, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) with a Buy rating and announced a price target of $12. Achieve Life Sciences shares closed at $4.53 on Wednesday. See how other analysts view this stock.</li>
<li>Oppenheimer analyst Ian Zaffino initiated coverage on Turning Point Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) with an Outperform rating and announced a price target of $65. Turning Point Brands shares closed at $55.00 on Wednesday. <a href="https://www.benzinga.com/quote/TPB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rodman &amp; Renshaw analyst Brandon Folkes initiated coverage on Rockwell Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy rating and announced a price target of $5. Rockwell Medical shares closed at $2.63 on Wednesday. <a href="https://www.benzinga.com/quote/RMTI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TPB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14075258/image-152-1024x544.png" alt="" class="wp-image-647827" style="width:811px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14075258/image-152-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14075258/image-152-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14075258/image-152-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14075258/image-152.png 1217w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41962884/us-stocks-settle-mixed-following-inflation-data-investor-sentiment-improves-but-fear-index-remains-in-greed-zone">US Stocks Settle Mixed Following Inflation Data: Investor Sentiment Improves, But Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Initiation

Pre-Market Outlook

Trading Ideas

ACHV

ADIL

This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Rodman &amp; Renshaw analyst Brandon Folkes initiates coverage on Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy rating and announces Price Target of $5.

Rodman & Renshaw Initiates Coverage On Rockwell Medical with Buy Rating, Announces Price Target of $5

Rockwell Medical Files For Stock Offering Of Up To $25M

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock rose 61.6% to $0.21 during Tuesday's pre-market session. The company's market cap stands at $2.5 million. As per the news, the Q3 earnings report came out today. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares increased by 46.12% to $0.29. The market value of their outstanding shares is at $43.0 million. </li>
<li>Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) shares increased by 28.75% to $6.85. The market value of their outstanding shares is at $255.3 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLDP#NASDAQ">CCLDP</a>) shares rose 28.17% to $15.97. </li>
<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares rose 27.56% to $2.08. The company's market cap stands at $426.1 million. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) shares moved upwards by 22.6% to $3.2. The market value of their outstanding shares is at $51.8 million. As per the press release, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) stock decreased by 40.2% to $1.1 during Tuesday's pre-market session. The market value of their outstanding shares is at $166.8 million. As per the press release, Q3 earnings came out today. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) stock decreased by 31.36% to $49.1. The company's market cap stands at $728.0 million. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) shares declined by 27.28% to $0.8. The market value of their outstanding shares is at $24.2 million. The company's, Q3 earnings came out today. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares decreased by 25.81% to $3.45. The market value of their outstanding shares is at $107.0 million. The company's, Q3 earnings came out today. </li>
<li>Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) stock fell 25.3% to $16.27. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares declined by 18.4% to $0.82. The market value of their outstanding shares is at $116.1 million. As per the press release, Q3 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CCLD

CCLDP

CERO

HRTX

LGMK

NGNE

NVRO

SNDX

STIM

TSHA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Press Releases

Rockwell Medical Promotes Jesse Neri to Chief Financial Officer

Markets

Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card

UPDATE: Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card

Rockwell Medical Enters into a Multi-Year Product Purchase Agreement with the World's Leading Provider of Dialysis Products and Services

Rockwell Medical Adds Single-Use Bicarbonate Cartridge to Hemodialysis Concentrates Product Portfolio

Rockwell Medical to Release Fourth Quarter and Full-Year 2024 Results on Thursday, March 20, 2025

Rockwell Medical Named 'Great Place to Work' for Third Year in a Row

Rockwell Medical to Exhibit at DialysisTechConneXion42 in Booth# 112

Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results

Comments

Rockwell Medical

Rockwell Medical (RMTI) Opzioni

Rockwell Medical (NASDAQ:RMTI) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO